1. TrumpRx Anchor Companies Spent $130M Lobbying as Drug Pricing Plan Took Shape — Nearly 23% Surge Outpacing Industry
The 17 pharmaceutical companies anchoring the Trump administration's new prescription drug-pricing program — TrumpRx — collectively poured more than $130 million into federal lobbying in 2025, a spending surge that outpaced the broader industry by nearly 23% as the plan was being shaped behind closed doors, according t...